Biomarkers.

Background: In the context of pathological aging and Alzheimer's disease (AD), the overexpression of calcineurin has been identified as a factor linked to astrocyte reactivity, neuronal death, and inflammation. This suggests that inhibiting calcineurin or downstream nuclear factor of activated T cells (NFAT) signaling could be a promising strategy for preventing or slowing down AD pathophysiology.

Method: Baseline and annual MRI sessions including higher-order diffusion-weighted imaging was performed over four years on 43 dogs ranging from 5 to 8.

Public Health.

Background: We analyzed the clinical care pathway of patients from symptom development to diagnosis at varying stages of Alzheimer's disease (AD) to understand the path and barriers to diagnosis.

Methods: Data were from the US Adelphi Real World Dementia Disease Specific Programme™ (cross-sectional survey of physicians and their patients with retrospective data collection) between December 2022 and September 2023. Physicians (primary care physicians [PCPs] and specialists) reported patient characteristics and disease severity, and patients reported their disease experience.

Developing Topics.

Background: Alzheimer's disease is the sixth most common cause of death in the United States (U.S.), with one in three adults 65 years of age and older dying of the disease each year.

Acute Myeloid Leukaemia and Acute Lymphoblastic Leukaemia Classification and Metabolic Characteristics for Informing and Advancing Treatment.

Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) remain significant challenges in haematological oncology. This review examines the pathophysiology, classification, and risk stratification of these aggressive malignancies, emphasising their impact on treatment strategies and prognosis. We discuss current standard-of-care treatments, including chemotherapy regimens and targeted therapies, while addressing the associated adverse effects and hypersensitivity reactions.